[go: up one dir, main page]

MA31430B1 - Formulation a liberation prolongee de nevirapine - Google Patents

Formulation a liberation prolongee de nevirapine

Info

Publication number
MA31430B1
MA31430B1 MA32400A MA32400A MA31430B1 MA 31430 B1 MA31430 B1 MA 31430B1 MA 32400 A MA32400 A MA 32400A MA 32400 A MA32400 A MA 32400A MA 31430 B1 MA31430 B1 MA 31430B1
Authority
MA
Morocco
Prior art keywords
nevirapine
release formulation
prolonged release
prolonged
pharmaceutical composition
Prior art date
Application number
MA32400A
Other languages
Arabic (ar)
English (en)
Inventor
Michael L Cappola
Svetlana Sienkiewicz
Glenn Charles Snow
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31430(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA31430B1 publication Critical patent/MA31430B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique à libération prolongée comprenant de la névirapine.
MA32400A 2007-06-08 2009-12-07 Formulation a liberation prolongee de nevirapine MA31430B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08
PCT/US2008/065705 WO2008154234A2 (fr) 2007-06-08 2008-06-04 Formulation à libération prolongée de névirapine

Publications (1)

Publication Number Publication Date
MA31430B1 true MA31430B1 (fr) 2010-06-01

Family

ID=39739795

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32400A MA31430B1 (fr) 2007-06-08 2009-12-07 Formulation a liberation prolongee de nevirapine

Country Status (28)

Country Link
US (1) US8460704B2 (fr)
EP (1) EP2155169B1 (fr)
JP (1) JP5417662B2 (fr)
KR (1) KR101017862B1 (fr)
CN (1) CN101784263B (fr)
AR (1) AR066924A1 (fr)
AU (1) AU2008262031B2 (fr)
BR (1) BRPI0811732A2 (fr)
CA (1) CA2687491C (fr)
CL (1) CL2008001678A1 (fr)
CO (1) CO6150128A2 (fr)
DK (1) DK2155169T3 (fr)
EA (1) EA018377B1 (fr)
EC (1) ECSP099561A (fr)
ES (1) ES2574836T3 (fr)
HU (1) HUE028598T2 (fr)
IL (1) IL199924A0 (fr)
MA (1) MA31430B1 (fr)
MX (1) MX2009007764A (fr)
NZ (1) NZ578664A (fr)
PE (2) PE20131035A1 (fr)
PL (1) PL2155169T3 (fr)
TN (1) TN2009000510A1 (fr)
TW (1) TWI419716B (fr)
UA (1) UA97971C2 (fr)
UY (1) UY31128A1 (fr)
WO (1) WO2008154234A2 (fr)
ZA (1) ZA200904939B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
DK2155169T3 (en) 2007-06-08 2016-06-13 Boehringer Ingelheim Int Formulation of nevirapine extended release
WO2009158704A2 (fr) 2008-06-27 2009-12-30 Duke University Agents thérapeutiques comprenant des peptides de type élastine
EP2714045A1 (fr) 2011-05-30 2014-04-09 Cipla Limited Composition pharmaceutique antirétrovirale
US20130084277A1 (en) * 2011-08-24 2013-04-04 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
IN2014MN01907A (fr) * 2012-03-05 2015-07-10 Cipla Ltd
CN104523630B (zh) * 2015-01-22 2017-08-25 山东新时代药业有限公司 一种奈韦拉平片剂
EP3153157A1 (fr) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Composition pharmaceutique à libération prolongée de névirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (fr) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines et leur utilisation pour la prevention ou le traitement de l'infection par le hiv
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
ATE216220T1 (de) 1997-12-05 2002-05-15 Alza Corp Osmotische darreichungsform mit zwei mantelschichten
DK1140012T3 (da) * 1998-12-17 2004-07-12 Alza Corp Omdannelse af væskefyldte gelatinekapsler til systemer til kontrolleret frigivelsessystemer ved flere coatinger
EE05022B1 (et) * 1999-03-31 2008-06-16 Janssen Pharmaceutica N.V. Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
KR100785360B1 (ko) * 1999-09-24 2007-12-18 얀센 파마슈티카 엔.브이. 항바이러스 조성물
KR100738276B1 (ko) 1999-12-09 2007-07-12 알자 코포레이션 항바이러스성 약제
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (fr) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Utilisation de nevirapine pour traiter ou prevenir des pathologies lipidiques chez des patients presentant une infection par vih resistante a la nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
AU2003287666A1 (en) 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
WO2004112724A2 (fr) 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions et procedes de traitement du vih
DE602004005734T2 (de) 2003-10-01 2007-12-27 Lupin Ltd., Mumbai Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung
PT1696822E (pt) 2003-11-13 2010-04-28 Psivida Inc Implante de libertação controlada injectável com um núcleo de matriz biocorrosível e crosta biocorrosível
WO2006024668A1 (fr) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US20110104267A1 (en) * 2005-04-25 2011-05-05 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
WO2007000779A2 (fr) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Nouvelles compositions pharmaceutiques a liberation prolongee et procedes pour leur preparation
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1933815A2 (fr) * 2005-10-14 2008-06-25 Microdose Technologies Inc. Conditionnement pharmaceutique d'une combinaison posologique orale
DK2155169T3 (en) 2007-06-08 2016-06-13 Boehringer Ingelheim Int Formulation of nevirapine extended release

Also Published As

Publication number Publication date
US8460704B2 (en) 2013-06-11
JP5417662B2 (ja) 2014-02-19
TW200916127A (en) 2009-04-16
ES2574836T3 (es) 2016-06-22
AR066924A1 (es) 2009-09-23
CA2687491C (fr) 2011-09-20
PL2155169T3 (pl) 2016-09-30
ECSP099561A (es) 2009-09-29
UY31128A1 (es) 2009-01-30
TN2009000510A1 (en) 2011-03-31
EA018377B1 (ru) 2013-07-30
NZ578664A (en) 2011-11-25
JP2010520891A (ja) 2010-06-17
BRPI0811732A2 (pt) 2014-11-18
AU2008262031B2 (en) 2011-08-25
WO2008154234A9 (fr) 2009-11-26
WO2008154234A2 (fr) 2008-12-18
AU2008262031A1 (en) 2008-12-18
EA200900958A1 (ru) 2010-04-30
CO6150128A2 (es) 2010-04-20
CN101784263B (zh) 2012-11-07
CN101784263A (zh) 2010-07-21
HK1145806A1 (en) 2011-05-06
UA97971C2 (ru) 2012-04-10
MX2009007764A (es) 2009-09-10
TWI419716B (zh) 2013-12-21
WO2008154234A3 (fr) 2010-01-21
IL199924A0 (en) 2010-04-15
EP2155169B1 (fr) 2016-03-23
DK2155169T3 (en) 2016-06-13
PE20131035A1 (es) 2013-10-01
CL2008001678A1 (es) 2009-09-11
US20100278918A1 (en) 2010-11-04
EP2155169A2 (fr) 2010-02-24
CA2687491A1 (fr) 2008-12-18
KR20100020447A (ko) 2010-02-22
PE20090371A1 (es) 2009-04-24
KR101017862B1 (ko) 2011-03-04
ZA200904939B (en) 2010-04-28
HUE028598T2 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
MA31430B1 (fr) Formulation a liberation prolongee de nevirapine
EP2093237A4 (fr) Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
FR21C1040I1 (fr) Formulations d'anticorps anti-cd20
EP2130552A4 (fr) Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingredient actif
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
EP2078731A4 (fr) Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
MA33761B1 (fr) Dispersion solide de rifaximine
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
FR14C0069I2 (fr) Composition pharmaceutique comprenant le lurasidone
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
CR10479A (es) Modulares bencimidazolicos de vr1
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
MA30042B1 (fr) Composes calcilytiques
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
MA34709B1 (fr) Compositions pharmaceutiques
EP2433987A4 (fr) Composition destinée à la préparation de formulations d'émulsion ou de microémulsion
NO20064808L (no) Orale matrixformuleringer med licarbazepin
EP2124963A4 (fr) Composition contenant un acide bisphosphonique combiné à de la vitamine d
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
CO5690567A2 (es) Formulaciones de tableta de liberacion extendida de venlafaxina